Skip to Content

Label Changes for:

AzaSite (azithromycin ophthalmic solution)

July 2012

Changes have been made to the CONTRAINDICATIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 


July 2012


  • Hypersensitivity to any component of this product 


March 2011 



Anaphylaxis and Hypersensitivity with Systemic Use of Azithromycin
  • In patients receiving systemically administered azithromycin, serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. The potential for anaphylaxis or other hypersensitivity reactions should be considered based on known hypersensitivity to azithromycin when administered systemically.


  • Section strengthened.